Colorectal Cancer _ ___________________________________________________________________________
65. What is the only potentially curative treatment for patients with locally recurrent or liver- and/or lung- only metastatic colon or rectal cancer? A) Targeted therapy B) Surgical resection C) Clinical trial enrollment D) Combination chemotherapy and radiation therapy 66. Which of the following factors would make hepatic metastases unsuitable for resection? A) Excessive number of lesions B) Intrahepatic location of lesions
68. Which of the following is TRUE of the skin toxicity profile unique to anti-EGFR agents? A) It may manifest in abnormal growth of eyelash length. B) Severity is associated with better cancer-control outcome. C) Prophylactic topical steroid, doxycycline, and moisturizer use may be helpful. D) All of the above 69. Following resection of colon cancer, 85% of recurrences occur within A) one year.
C) Lack of major vascular involvement D) Sufficient functional hepatic reserve
B) three years. C) five years. D) 10 years.
67. Compared with systemic chemotherapy, hepatic intra-arterial chemotherapy for liver metastases is associated with
70. Use of post-treatment CEA testing is usually limited to patients A) with stage I colorectal cancer. B) with stage II or III colorectal cancer. C) who would not be candidates for resection of lung metastases. D) who would not be candidates for resection of liver metastases.
A) greater liver dysfunction. B) comparable response rates. C) lower likelihood of fatal toxicity. D) improved median and overall survival.
Course Code: MDFL15CC
94
MDFL2626
Powered by FlippingBook